Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: For the past decades, the long-term results of renal allograft unchanged despite the development of immunology and drugs. The long-term use of a calcineurin-inhibitor (CNI) and medication nonadherence have become important issues affecting long-term results. The combination of the once-daily advagraf and sirolimus was proposed as a good alternative with such reasons. The purpose of this study was the analysis of the clinical advantages of oncedaily advagraf and sirolimus combination by decreasing the use of CNI and improving medication adherence in stable kidney recipients. Materials and methods: In this study, 34 patients who switched from their present medication to a once-daily advagraf and sirolimus combination at Korea University Anam Hospital from September 2011 to March 2013 were retrospectively reviewed for 24 months. Laboratory findings, clinical findings, and medication adherence were reviewed and analyzed. Results: After conversion to the new regimen, renal function was slightly improved at 3 months, as evidenced by creatinine levels (p = 0.024) and EGFR (p < 0.001). Lipid profiles deteriorated throughout the study period. Serum fast glucose level and proteinuria increased significantly at 12 months but recovered at 24 months. On the Morisky-Green test (MGT) for medication adherence, there were adherent improvements of 23.33% after 12 months and 16.66% after 24 months. Conclusion: The once-daily advagraf and sirolimus combination can be a safe and effective regimen in stable kidney recipients as the study shows that the regimen improves renal function and medication adherence with controllable adverse effects of sirolimus.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalInternational Journal of Clinical Pharmacology and Therapeutics
Volume54
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Medication Adherence
Sirolimus
Kidney
Korea
Allergy and Immunology
Proteinuria
Allografts
Creatinine
Lipids
Glucose
Serum
Pharmaceutical Preparations

Keywords

  • Advagraf and sirolismus combination
  • Medication adherence
  • Renal transplantation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{3eb2bc9478504b9d849d6aab9734b489,
title = "Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients",
abstract = "Purpose: For the past decades, the long-term results of renal allograft unchanged despite the development of immunology and drugs. The long-term use of a calcineurin-inhibitor (CNI) and medication nonadherence have become important issues affecting long-term results. The combination of the once-daily advagraf and sirolimus was proposed as a good alternative with such reasons. The purpose of this study was the analysis of the clinical advantages of oncedaily advagraf and sirolimus combination by decreasing the use of CNI and improving medication adherence in stable kidney recipients. Materials and methods: In this study, 34 patients who switched from their present medication to a once-daily advagraf and sirolimus combination at Korea University Anam Hospital from September 2011 to March 2013 were retrospectively reviewed for 24 months. Laboratory findings, clinical findings, and medication adherence were reviewed and analyzed. Results: After conversion to the new regimen, renal function was slightly improved at 3 months, as evidenced by creatinine levels (p = 0.024) and EGFR (p < 0.001). Lipid profiles deteriorated throughout the study period. Serum fast glucose level and proteinuria increased significantly at 12 months but recovered at 24 months. On the Morisky-Green test (MGT) for medication adherence, there were adherent improvements of 23.33{\%} after 12 months and 16.66{\%} after 24 months. Conclusion: The once-daily advagraf and sirolimus combination can be a safe and effective regimen in stable kidney recipients as the study shows that the regimen improves renal function and medication adherence with controllable adverse effects of sirolimus.",
keywords = "Advagraf and sirolismus combination, Medication adherence, Renal transplantation",
author = "Heungman Jun and Myung-Gyu Kim and Jung, {Cheol Woong}",
year = "2016",
month = "2",
day = "1",
doi = "10.5414/CP202518",
language = "English",
volume = "54",
pages = "81--86",
journal = "International Journal of Clinical Pharmacology and Therapeutics",
issn = "0946-1965",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

TY - JOUR

T1 - Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients

AU - Jun, Heungman

AU - Kim, Myung-Gyu

AU - Jung, Cheol Woong

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose: For the past decades, the long-term results of renal allograft unchanged despite the development of immunology and drugs. The long-term use of a calcineurin-inhibitor (CNI) and medication nonadherence have become important issues affecting long-term results. The combination of the once-daily advagraf and sirolimus was proposed as a good alternative with such reasons. The purpose of this study was the analysis of the clinical advantages of oncedaily advagraf and sirolimus combination by decreasing the use of CNI and improving medication adherence in stable kidney recipients. Materials and methods: In this study, 34 patients who switched from their present medication to a once-daily advagraf and sirolimus combination at Korea University Anam Hospital from September 2011 to March 2013 were retrospectively reviewed for 24 months. Laboratory findings, clinical findings, and medication adherence were reviewed and analyzed. Results: After conversion to the new regimen, renal function was slightly improved at 3 months, as evidenced by creatinine levels (p = 0.024) and EGFR (p < 0.001). Lipid profiles deteriorated throughout the study period. Serum fast glucose level and proteinuria increased significantly at 12 months but recovered at 24 months. On the Morisky-Green test (MGT) for medication adherence, there were adherent improvements of 23.33% after 12 months and 16.66% after 24 months. Conclusion: The once-daily advagraf and sirolimus combination can be a safe and effective regimen in stable kidney recipients as the study shows that the regimen improves renal function and medication adherence with controllable adverse effects of sirolimus.

AB - Purpose: For the past decades, the long-term results of renal allograft unchanged despite the development of immunology and drugs. The long-term use of a calcineurin-inhibitor (CNI) and medication nonadherence have become important issues affecting long-term results. The combination of the once-daily advagraf and sirolimus was proposed as a good alternative with such reasons. The purpose of this study was the analysis of the clinical advantages of oncedaily advagraf and sirolimus combination by decreasing the use of CNI and improving medication adherence in stable kidney recipients. Materials and methods: In this study, 34 patients who switched from their present medication to a once-daily advagraf and sirolimus combination at Korea University Anam Hospital from September 2011 to March 2013 were retrospectively reviewed for 24 months. Laboratory findings, clinical findings, and medication adherence were reviewed and analyzed. Results: After conversion to the new regimen, renal function was slightly improved at 3 months, as evidenced by creatinine levels (p = 0.024) and EGFR (p < 0.001). Lipid profiles deteriorated throughout the study period. Serum fast glucose level and proteinuria increased significantly at 12 months but recovered at 24 months. On the Morisky-Green test (MGT) for medication adherence, there were adherent improvements of 23.33% after 12 months and 16.66% after 24 months. Conclusion: The once-daily advagraf and sirolimus combination can be a safe and effective regimen in stable kidney recipients as the study shows that the regimen improves renal function and medication adherence with controllable adverse effects of sirolimus.

KW - Advagraf and sirolismus combination

KW - Medication adherence

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=84958794143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958794143&partnerID=8YFLogxK

U2 - 10.5414/CP202518

DO - 10.5414/CP202518

M3 - Article

C2 - 26709601

AN - SCOPUS:84958794143

VL - 54

SP - 81

EP - 86

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 2

ER -